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Summary
The aim of this study was to compare the prevalence and factors associated with genital tract
infections among HIV-infected pregnant women from African sites. Participants were recruited from
Blantyre and Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia. Genital tract
infections were assessed at baseline. Of 2627 eligible women enrolled, 2292 were HIV-infected. Of
these, 47.8% had bacterial vaginosis (BV), 22.4% had vaginal candidiasis, 18.8% had trichomoniasis,
8.5% had genital warts, 2.6% had chlamydia infection, 2.2% had genital ulcers and 1.7% had
gonorrhoea. The main factors associated with genital tract infections included genital warts (adjusted
odds ratio [AOR] 1.8, 95% CI 1.2–2.7), genital ulcers (AOR 2.4, 95% CI 1.2–5.1) and abnormal
vaginal discharge (AOR 2.5, 95% CI 1.9–3.3) for trichomoniasis. BV was the most common genital
tract infection followed by candidiasis and trichomoniasis. Differences in burdens and risk factors
call for enhanced interventions for identification of genital tract infections among HIV-infected
women.
Keywords
sexually transmitted infections; genital tract infections; pregnant women; human immunodeficiency
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INTRODUCTION
Genital tract infections are known to facilitate the sexual transmission of HIV type 1.1–3
Genital tract infections are a major global cause of acute illness, infertility, long-term disability
with severe medical and psychological consequences affecting millions of men, women and
children. The World Health Organization (WHO) estimated that 340 million cases of syphilis,
gonorrhoea, chlamydia infection and trichomoniasis occurred throughout the world in 1999 in
men and women aged 15–49 years.4 Data from epidemiological surveys show that within
countries and between countries in the same region, the prevalence and incidence of genital
tract infections may vary widely even in similar population groups.4
Identifying factors associated with genital tract infections in HIV-infected pregnant women in
diverse African population can contribute to the development of prevention and control
strategies. The aim of this study was to compare the prevalence and risk factors associated with
genital tract infections among HIV-infected pregnant women enrolled in a clinical trial in
Blantyre and Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia (HPTN 024).
MATERIALS AND METHODS
HPTN 024 trial
The HPTN 024 trial was a randomized, double-blinded, placebo-controlled Phase III trial
which enrolled both HIV-infected and -uninfected pregnant women. The primary objective of
this clinical trial was to determine the efficacy of a low-cost antibiotic intervention for
prevention of chorioamnionitis-associated mother-to-child transmission (MTCT) of HIV and
of preterm birth.5 This multicenter trial was conducted at clinical sites in four sub-Saharan
African cities: Blantyre and Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia.
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The trial was approved by USA and in-country institutional ethical review boards or
committees in each country. Written informed consents were obtained from all enrolled
participants. Enrolment commenced in July 2001 and ended in February 2003. The methods
of the trial have been described elsewhere.5
Data on sociodemographic characteristics and sexual history were obtained through participant
interview at the enrolment visit (20–24 weeks gestation). The external genitalia, vagina and
cervix were examined and a bimanual examination was performed. Laboratory investigations
included HIV-1 serology screening by dual rapid-testing algorithm and western blot
confirmation of all positive or indeterminate results at Blantyre, Lilongwe and Lusaka sites.
Dar es Salaam site performed two enzyme-linked immunosorbent assays (ELISAs); Dade
Behring Enzygnost anti-HIV-1/2 Plus as first ELISA followed by Abbott Murex Wellcozyme
anti-HIV-1 recombinant with discrepant results between the two ELISAs being confirmed by
western blot. In addition, laboratory screening for the following genital tract infections was
performed: syphilis,6 trichomoniasis, vaginal candidiasis, bacterial vaginosis (BV) (diagnosed
by Nugent score), gonorrhoea and chlamydia infection. Women were screened for syphilis
using rapid plasma reagin (RPR) test (Blantyre, Lilongwe and Lusaka) or Venereal Disease
Research Laboratory test (Dar es Salaam). Confirmation of the syphilis screening was
performed with the microhaemagglutination Treponema pallidum test (MHA-TP) (Lilongwe),
T. pallidum particle agglutination test (TPPA; Dar es Salaam) or T. pallidum haemagglutination
assay (TPHA; Blantyre). Both TPPA and TPHA tests were used to confirm positive RPR
samples from Lusaka. Women with confirmed syphilis were treated with intramuscular
benzathine penicillin at no cost. A sterile cotton-tipped applicator, used to swab the lateral
vaginal wall, was placed in a test tube container containing 1 mL sterile saline. The fluid was
examined in the site laboratory for the presence of motile Trichomonas vaginalis, clue cells
and hyphae buds. Cotton-tipped applicator was also used to collect vaginal specimen for Gram
stain. Applicator was gently rolled (not rubbed) across the surface of a glass slide to create a
monolayer of cells. The slide was then allowed to air-dry, and then stored at room temperature
in a slide box. The slides were then shipped to University of Alabama at Birmingham for
evaluation. For BV, women were considered positive if they had a Nugent score ≥7. The Nugent
score is based on counting the bacterial cell types on Gram-stained slides of vaginal smears.
7 For gonococcal culture, cotton-tipped swab was placed in the endocervical canal and allowed
to sit for at least 10 s. This swab was then used to inoculate a plate for gonococcal isolation.
The inoculated plate was then stored in a candle jar in the clinic and immediately transported
to the site laboratory for streaking. The plates were incubated in a candle jar at 37°C and
inspected at 24 and 48 hours. Neisseria gonorrhoeae were identified by typical Gram stain
appearance and positive oxidase reaction. Dacron swabs provided in the manufacturer’s
collection kit (Syva MicroTrak) were placed in the endocervical canal and allowed to sit for
at least 10 s. They were placed in the vial provided, the handle of the swab was snapped-off
and the vials were capped for transport to the site laboratory. Chlamydia trachomatis antigen
was extracted from the swabs and enzyme immunosorbent assay was performed on the extract
according to the manufacturer’s instructions (Syva MicroTrak). Flow cytometry for CD4 count
was also performed. HIV-infected women and their infants were offered MTCT prophylaxis
with Nevirapine 200 mg during labour onset and 2 mg/kg for infants within 72 hours of birth.
8
Study population for this analysis
All HIV-infected pregnant women who had been screened for the genital tract infections were
included in the analyses. HIV-uninfected pregnant women were excluded because not all four
clinical sites recruited HIV-uninfected women.
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Sociodemographic characteristics of the study population were assessed among women from
the four clinical sites. The prevalences of the following genital tract infections were calculated
in univariate analysis (overall and by site): trichomoniasis, vaginal candidiasis, BV (based on
Nugent score), gonorrhoea, Chlamydia infection, genital warts and genital ulcers. Data
regarding syphilis correlated with HIV-infected pregnant women enrolled in HPTN 024 trial
and were published in another study.6 χ2 Tests or t-tests were conducted to assess the statistical
associations between each genital tract infection and sociodemographic characteristics, sexual
history, pelvic examination findings in univariate analyses, respectively.
Multiple logistic regression analyses were performed to obtain AORs for the variables of
interest, for each outcome. Due to the large number of variables, a model building strategy
using deviance tests was employed. A complete model containing all variables of interest was
initially fitted; this model was then reduced by removing variables with P values greater than
0.4 and comparing the change in deviance between the two models. If the change in deviance
was not significant, more variables were removed (using P > 0.4 criteria) from the reduced
model. This procedure was repeated until a significant change in deviances was observed.
Findings are presented as AOR, 95% CI and P value for the individual variables. All the
statistical analyses were performed with SAS™ version 9.1 (SAS, Inc., Cary, NC, USA).
RESULTS
Size and characteristics of the study population
Overall, 2627 eligible women were enrolled in the HPTN 024 trial. Of this, 2292 (87.2%) were
HIV-infected. All these women were screened for genital tract infections. Thus, the study
population comprised 2292 women, of whom 474 (20.7%) were from Blantyre, 748 (32.6%)
from Lilongwe, 428 (18.7%) from Dar es Salaam and 642 (28%) from Lusaka. Baseline
sociodemographic and sexual history characteristics of the study population, overall and
stratified by clinical site are shown in Table 1. The distribution of all these characteristics varied
significantly across sites. Findings on pelvic examination, overall and stratified by clinical site
are shown in Table 1. The proportion of subjects with vaginal bleeding, cervical abnormalities
(discharge, friability/epithelial disruption, vesicles, ulcerations, and ectopy), adnexal and
uterine tenderness, and adnexal masses differed significantly by site.
Prevalences of genital tract infections
Overall, the most common genital tract infection was BV and the least common was genital
ulcers (Table 2). There were statistically significant differences in the prevalences of genital
tract infections by site for all infections except genital warts and genital ulcer (Table 2). The
highest prevalence of genital tract infection by site was: BV (60.6%) in Dar es Salaam,
candidiasis (29.0%) in Blantyre, trichomoniasis (24.1%) and gonorrhoea (3.6%) in Lilongwe,
genital warts (9.5%) and chlamydia infection (6.1%) in Lusaka.
Factors associated with genital tract infections
Univariate analyses of factors associated with genital tract infections are shown in Table 3
(trichomoniasis, vaginal candidiasis and BV) and Table 4 (gonorrhoea and chlamydia
infection). Sociodemographic characteristics (formal employment, marital status, spouse
occupation, Blantyre site, housing and cook with stove, firewood) and sexual history (lifetime
sexual partners), along with certain pelvic examination findings (genital warts, genital ulcers,
vaginal bleeding, abnormal vaginal discharge, cervical discharge and 1–25% ectopy), were
associated with trichomoniasis, vaginal candidiasis and BV. Fewer of such factors were
associated with gonorrhoea or chlamydia infection.
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The results of multiple logistic regression analyses of factors associated with the five genital
tract infections are shown in Tables 5 and 6. Factors associated with trichomoniasis were:
education of the sexual partner, site (Dar es Salaam), treatment for genital ulcers, genital warts,
genital ulcers and abnormal vaginal discharge. Factors associated with vaginal candidiasis
included lifetime sexual partners, abnormal vaginal discharge and CD4 count. Only
sociodemographic factors (spouse’s occupation and clinical site) were associated with BV.
Only socio-demographic (maternal age, clinical site) and sexual history (treated for genital
ulcers in the past year) were associated with gonorrhea. Finally, only clinical site was associated
with chlamydia infection.
DISCUSSION
Among HIV-infected pregnant women who presented for antenatal care at sites in Malawi,
Tanzania and Zambia, the prevalences of genital tract infections were generally high. The
prevalence of trichomoniasis was very high at all sites except Dar es Salaam despite the fact
that the technique used to diagnose trichomoniasis entailed microscopic examination of wet-
mount preparation, a relatively insensitive method. Dar es Salaam, Tanzania having the lowest
prevalence of trichomoniasis (4.2%) is in contrast with the recent report from Ministry of
Health documenting higher rates and noting that Dar es Salaam was among the regions that
reported the highest number of genital tract infections among antenatal clinic attendees.9 This
apparent difference could be due to the use of syndromic approach to diagnosis in the later
report compared with the laboratory-based diagnostic approach used in the current study.
We noted a high prevalence of BV across all sites and Dar es Salaam had the highest prevalence
of BV (60.6%). This condition has important implications in the context of HIV infection. For
example, one study suggested that disturbances of vaginal flora and BV were associated with
an increased risk of HIV acquisition during pregnancy.10 The utility of Nugent score and
leukocyte count in vaginal secretions for BV diagnosis has been documented.11
The genital tract infection with the lowest prevalence in all settings in our study population
was gonorrhoea. The prevalences of gonorrhoea and other genital tract infections such as
trichomoniasis and genital ulcers in HIV-infected women in Malawi are similar to those
reported earlier, although genital warts appear to be on the increase (2.7% in 1995 vs. currently
8.9%).12 The prevalence of gonorrhoea (0.4% vs. 3.6%) was found to be significantly higher
in Lilongwe (3.6%) when compared with Blantyre (0.4%) (P < 0.0001). Populations from both
the sites are similar in sociodemographic and sexual behaviour characteristics. However, at
population level, the spread of a sexually transmitted infection (STI) depends on the average
number of new cases of infection generated by an infected person, health-seeking behaviour
and also differences in the access to appropriate treatment.4
Chlamydia infection was very low in Malawi but relatively high in Zambia. The highest
prevalence of chlamydia infection (6.1%) found in Lusaka compared with the other clinical
sites is noteworthy but difficult to explain. However, the prevalence is relatively low when
compared with the 9% prevalence of infection reported among female sex workers in other
cities in sub-Saharan Africa.13 Previous studies among pregnant women revealed a prevalence
rate of 6% in Tanzania, 12.4% in South Africa and 13% in Cape Verde.14–16
Women with five or more lifetime sexual partners were more likely to be diagnosed with
trichomoniasis compared with those having one lifetime partner. Findings of reported multiple
sexual partners has been documented previously to be a risk factor for gonorrhoea, chlamydia
infection17,18 and trichomoniasis.19 We also noted that having been treated for genital ulcer
disease in the last year was associated with lower risk for trichomoniasis. This finding provides
support for the concept that appropriate management of STIs reduces the risk of recurrent
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episodes of infection. We also found that abnormal vaginal discharge was strongly associated
with trichomoniasis and vaginal candidiasis. Similar findings about the coexistence of genital
ulcers and genital discharge have been reported recently in Uganda.20
Women at the Lilongwe site and those who received treatment for genital ulcer disease in the
prior year were more likely to be diagnosed with gonorrhoea. This may be explained by the
fact that having genital ulcer disease is a marker for high-risk behaviour that, if continued,
would put an individual to a future risk for gonorrhoea. The finding of genital ulcer disease
treatment during the last year being associated with gonorrhoea supports the significance of
previous medical history as well as treatment to predict the current status of genital tract
infections of an individual. More than two-thirds of women in the study had CD4 counts ≤500
cells/μL at enrolment and this was found to be a significant factor for vaginal candidiasis. A
10-year prospective study conducted among 1215 female sex workers in Nairobi, Kenya,
showed that risks of vaginal candidiasis and genital ulcer disease were significantly higher
among HIV-infected women than among HIV-uninfected women, and risks of the two diseases
rose with increasing level of immunosuppression.21
Noted strengths of our study are its large size and the inclusion of women from four cities in
sub-Saharan Africa with significant variations in sociodemographic and sexual behavioural
characteristics. One limitation of this study is that we are not able to comment on the prevalence
of genital tract infections or their predictors among the larger population of HIV-uninfected
women in these settings. Thus, the study findings cannot be generalized to all pregnant women
because the women in our study population could have been seeking research-related care,
perhaps due to known HIV infection, obstetrical complications or genital tract infections.
BV was the most common genital tract infection followed by candidiasis and trichomoniasis.
The different genital tract infection burdens in different settings, and difference in risk factors
for such infections across sites, call for enhanced interventions for the identification of genital
tract infections among HIV-infected women.
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Table 3
Univariate analyses of factors associated with trichomoniasis, vaginal candidiasis





UOR (95% CI) BV UOR (95% CI)
Sociodemographic
Maternal age at enrolment (per five year
increase)
0.8 (0.7–0.9) 1.0 (0.9–1.1) 0.9 (0.8–1.0)
Years of education (per one year increase) 0.9 (0.9–1.0) 1.0 (1.0–1.0) 0.9 (0.9–1.0)
Occupation
Self-employed 1.0 1.0 1.0
Formal employment 1.1 (0.7–1.8) 1.2 (0.8–1.9) 1.7 (1.2–2.5)
Homemaker 1.2 (0.9–1.7) 0.9 (0.7–1.3) 2.0 (1.5–2.6)
Other 1.9 (0.9–3.8) 1.0 (0.5–2.1) 0.9 (0.5–1.7)
Marital status
Married 1.0 1.0
Other 0.7 (0.5–1.0) 1.1 (0.7–1.6) 2.0 (1.5–2.8)
Partner years of education
One year increase 0.9 (0.9–1.0) 1.0 (1.0–1.1) 1.0 (0.9–1.0)
Spouse occupation
Self-employed 1.0 1.0 1.0
Formal employment 1.1 (0.9–1.4) 1.0 (0.8–1.3) 1.1 (0.9–1.3)
None 1.2 (0.7–2.1) 0.8 (0.4–1.4) 1.7 (1.1–2.8)
Other 0.9 (0.4–2.0) 0.7 (0.3–1.6) 0.5 (0.3–0.9)
Site
Lusaka 1.0 1.0 1.0
Blantyre 1.0 (0.7–1.3) 1.7 (1.3–2.2) 1.7 (1.3–2.1)
Lilongwe 1.2 (0.9–1.6) 1.4 (1.0–1.9) 931.6 (220.3 to >999.9)
Dar es Salaam 0.2 (0.1–0.3) 0.8 (0.8–1.3) 0.2 (0.1–0.3)
Housing
Stay with relatives 1.0 1.0 1.0
Own house 0.6 (0.4–0.9) 0.8 (0.5–1.3) 2.0 (1.3–2.9)
Rent house 0.6 (0.4–1.0) 0.8 (0.5–1.2) 1.9 (1.3–2.7)
Rent room 0.4 (0.2–0.6) 0.7 (0.5–1.2) 0.4 (0.3–0.6)
Staff quarters 0.5 (0.2–0.9) 0.9 (0.5–1.6) 1.7 (1.0–2.9)
Other 0.5 (0.1–4.4) 0.6 (0.1–5.0) 0.3 (0.03–2.4)
Cook with
Electric stove 0.8 (0.6–1.0) 0.9 (0.7–1.1) 2.0 (1.6–2.4)
Paraffin stove 0.3 (0.2–0.5) 0.9 (0.7–1.2) 5.3 (4.2–6.9)
Charcoal stove 0.9 (0.7–1.1) 1.0 (0.8–1.2) 1.4 (1.2–1.7)
Firewood 1.7 (1.4–2.1) 1.2 (1.0–1.5) 0.1 (0.1–0.11)
Sexual history
Lifetime sex partners
5+ 1.0 1.0 1.0
4 0.5 (0.3–0.9) 0.9 (0.5–1.4) 1.0 (0.7–1.4)


















UOR (95% CI) BV UOR (95% CI)
3 0.7 (0.5–1.1) 1.0 (0.7–1.5) 1.3 (0.9–1.8)
2 0.8 (0.6–1.2) 1.2 (0.8–1.8) 1.6 (1.2–2.1)
1 0.8 (0.5–1.1) 1.4 (1.0–2.1) 1.9 (1.3–2.6)
Number of partners during this pregnancy
2+ 1.0 1.0 1.0
1 0.9 (0.4–1.8) 1.5 (0.7–3.4) 1.8 (1.0–3.3)
0 0.9 (0.3–2.9) 3.1 (1.0–9.6) 2.3 (0.9–6.0)
Condom use
Always 1.0 1.0 1.0
Sometimes 1.5 (0.7–2.9) 0.7 (0.4–1.3) 0.9 (0.5–1.5)
Never 1.5 (0.8–2.9) 0.8 (0.5–1.4) 0.3 (0.2–0.5)
Last year syphilis treatment
Yes 1.0 1.0 1.0
No 1.1 (0.7–1.7) 1.0 (0.6–1.5) 0.6 (0.4–0.9)
Last year treated for genital ulcers
Yes 1.0 1.0 1.0
No 0.6 (0.3–1.1) 1.3 (0.8–2.1) 0.6 (0.3–1.0)
Last year vaginal discharge treatment
Yes 1.0 1.0 1.0




Yes 1.0 1.0 1.0
No 1.6 (1.2–2.3) 1.0 (0.7–1.4) 1.3 (1.0–1.7)
Genital ulcers
Yes 1.0 1.0 1.0
No 2.4 (1.3–4.3) 0.9 (0.4–1.8) 1.0 (0.6–1.8)
Vagina
Vaginal bleeding 4.9 (2.0–11.5) 0.6 (0.2–2.0) 4.3 (1.4–12.9)
Subepithelial haemorrhage 8.7 (0.8–95.9) 6.9 (0.6–76.5) 2.0 (0.2–22.2)
Oedema 4.3 (0.3–69.3) 3.5 (0.2–55.5) –
Condyloma – vagina 1.2 (0.6–2.6) 1.3 (0.6–2.6) 0.6 (0.3–1.1)
Vesicles 1.4 (0.3–7.3) 0.5 (0.1–4.0) 3.0 (0.6–15.0)
Bullae – – –
Vaginal epithelial disruption 1.2 (0.3–4.2) 1.9 (0.6–5.8) 1.8 (0.6–5.4)
Abnormal vaginal discharge 2.1 (1.7–2.7) 1.7 (1.3–2.3) 1.0 (0.8–1.2)
Cervix
Cervical discharge 1.4 (1.1–1.9) 0.9 (0.7–1.2) 1.2 (1.0–1.5)
Friability/epithelial disruption 1.6 (1.1–2.3) 0.6 (0.4–1.0) 0.9 (0.7–1.3)
Condyloma – cervix 1.9 (0.8–4.7) 1.2 (0.4–3.2) 0.8 (0.3–1.8)
Vesicles – cervix 3.2 (1.3–8.0) 0.6 (0.2–2.2) 1.7 (0.7–4.4)


















UOR (95% CI) BV UOR (95% CI)
Ulcerations 1.5 (1.0–2.3) 0.3 (0.2–0.6) 4.3 (2.7–7.1)
Ectopy
0% 1.0 – 1.0
1–25% 1.5 (1.2–1.9) 0.8 (0.7–1.0) 12.1 (9.5–15.5)
26–50% 1.4 (0.6–3.3) 0.6 (0.2–1.6) 5.0 (2.3–10.8)
Bimanual exam
Adnexal tenderness 2.1 (1.0–4.3) 1.8 (0.9–3.8) 0.5 (0.3–1.1)
Uterine tenderness 1.3 (0.4–4.1) 1.4 (0.5–4.1) 0.7 (0.3–1.8)
Adnexal masses 0.9 (0.2–4.0) 0.7 (0.2–3.1) 0.3 (0.1–1.2)
CD4 count (cells/μL)
>500 1.0 1.0 1.0
200–500 0.9 (0.8–1.2) 1.4 (1.0–1.8) 1.2 (0.9–1.4)
<200 0.7 (0.4–0.9) 1.5 (1.1–2.1) 1.0 (0.8–1.3)
UOR = unadjusted odds ratio; CI = confidence interval; BV = bacterial vaginosis
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Table 4
Univariate analyses of factors associated with gonorrhoea and Chlamydia infection
(n = 2292)
UOR (95% CI)
Associated factor Gonorrhoea Chlamydia
Sociodemographic
Maternal age at enrolment (per five year increase) 0.6 (0.4–0.9) 0.8 (0.6–1.0)
Years of education (per one year increase) 1.0 (0.9–1.0) 1.0 (0.9–1.1)
Occupation
Self-employed 1.0 1.0
Formal employment 1.0 (0.2–4.6) 0.4 (0.1–2.2)
Homemaker 1.2 (0.4–3.4) 1.2 (0.5–2.8)
Other 1.0 (0.3–4.5) 0.8 (0.1–7.1)
Marital status
Married 1.0 1.0
Other 1.1 (0.3–3.7) 1.2 (0.4–3.3)
Partner’s years of education
One year increase 1.0 (0.9–1.1) 1.0 (1.0–1.1)
Spouse’s occupation
Self-employed – 1.0
Formal employment – 0.7 (0.4–1.2)
None – 0.7 (0.2–3.1)
Other – 1.5 (0.7–3.5)
Site
Lusaka 1.0 1.0
Blantyre 0.3 (0.1–1.2) 0.1 (0.04–0.4)
Lilongwe 2.4 (1.1–4.9) 0.6 (0.3–1.1)
Dar es Salaam 0.2 (0.02–1.2) 0.04 (0.01–0.2)
Housing
Stay with relatives 1.0 1.0
Own house 2.1 (0.3–16.6) 0.6 (0.2–1.6)
Rent house 2.8 (0.4–21.0) 0.5 (0.2–1.4)
Rent room 1.8 (0.2–15.0) 1.2 (0.5–3.4)
Staff quarters 2.9 (0.3–33.0) 0.3 (0.03–2.7)
Other – –
Cook with
Electric stove 2.6 (0.8–8.4) 0.6 (0.3–1.0)
Paraffin stove 4.6 (1.1–19.3) 0.8 (0.4–1.5)
Charcoal stove 0.8 (0.4–1.6) 1.2 (0.7–2.1)
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UOR (95% CI)
Associated factor Gonorrhoea Chlamydia
4 0.9 (0.2–3.5) 1.6 (0.6–4.5)
3 1.2 (0.4–3.8) 1.0 (0.4–2.6)
2 0.8 (0.2–2.5) 0.7 (0.2–1.7)
1 0.7 (0.2–2.4) 0.6 (0.2–1.8)
Number of partners during this pregnancy
2+ 1.0 1.0
1 0.8 (0.1–5.9) 0.2 (0.1–0.5)





Received treatment for syphilis during the past year
Yes 1.0 1.0
No 1.5 (0.5–5.1) 0.6 (0.2–2.7)
Received treatment for genital ulcers during the past year
Yes 1.0 1.0
No 4.5 (1.9–11.1) 1.3 (0.4–4.3)
Received treatment for vaginal discharge during the past year
Yes 1.0 1.0





No 1.3 (0.4–3.6) 2.1 (1.0–4.3)
Genital ulcers
Yes 1.0 1.0
No 4.1 (1.2–13.8) 2.8 (0.8–9.3)
Vagina
Vaginal bleeding – 2.5 (0.3–19.1)
Subepithelial haemorrhage – –
Oedema –
Condyloma – vagina – 1.0 (0.1–7.4)
Vesicles – –
Bullae –
Abnormal vaginal discharge 1.2 (0.7–2.2)
Cervix
Cervical discharge 2.1 (1.1–4.2) –
Friability/epithelial disruption 1.5 (0.5–4.2) –
Condyloma – cervix 2.7 (0.4–21.0) –
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UOR (95% CI)
Associated factor Gonorrhoea Chlamydia







Adnexal tenderness 1.7 (0.2–13.0) –
Uterine tenderness – 2.3 (0.3–17.8)
Adnexal masses – –
CD4 count (cells/μL)
>500 1.0 1.0
200–500 1.0 (0.5–2.2) 1.4 (0.7–2.7)
<200 0.7 (0.2–.1.9) 1.1 (0.5–2.7)
UOR = unadjusted odds ratio; CI = confidence interval
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Table 5
Multivariate analyses of factors associated with Trichomoniasis, vaginal
candidiasis and bacterial vaginosis in the study population (n = 2292)
AOR (95% CI)
Associated factor Trichomoniasis Vaginal candidiasis BV
Sociodemographic
Maternal age at enrolment (per five
year increase)
0.8 (0.8–1.0) – 0.9 (0.8–1.0)
Years of education (per one year
increase)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
Partner’s years of education
One year increase 0.9 (0.9–1.0) 1.0 (1.0–1.1) –
Spouse’s occupation
Self–employed 1.0 1.0 1.0
Formal employment 1.2 (0.9–1.6) 1.0 (0.7–1.2) 1.2 (1.0–1.5)
None 0.9 (0.5–1.7) 1.0 (0.5–1.8) 1.8 (1.1–3.0)
Other 1.2 (0.5–3.0) 0.7 (0.3–1.5) 0.9 (0.4–1.7)
Site
Lusaka 1.0 1.0 1.0
Blantyre 1.0 (0.6–1.6) 1.5 (1.0–2.1) 1.6 (1.2–2.3)
Lilongwe 1.0 (0.6–1.6) 0.9 (0.7–1.2) 1.4 (0.9–2.0)
Dar es Salaam 0.2 (0.1–0.3) 1.3 (0.9–2.0) 1.8 (1.1–2.9)
Sexual history
Lifetime sex partners
1 1.0 1.0 –
2 1.1 (0.8–1.6) 0.9 (0.6–1.2) –
3 1.0 (0.7–1.4) 0.6 (0.4–0.9) –
4 0.8 (0.5–1.3) 0.6 (0.4–1.0) –
5+ 1.6 (1.0–2.6) 0.6 (0.4–1.0) –
Received treatment for genital ulcers during the past year
No 1.0 1.0 –
Yes 0.3 (0.1–07) 1.3 (0.7–2.3) –
Pelvic exam findings
Genital warts
No 1.0 1.0 1.0
Yes 1.8 (1.2–2.7) 0.8 (0.5–1.3) 1.2 (0.9–1.8)
Genital ulcers
No 1.0 – 1.0
Yes 2.4 (1.2–5.1) – 1.4 (0.7–3.0)
Abnormal vaginal discharge
No 1.0 1.0 1.0
Yes 2.5 (1.9–3.3) 1.7 (1.3–2.3) 0.9 (0.7–1.1)
CD4 count (cells/μL)
>500 1.0 1.0 1.0
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AOR (95% CI)
Associated factor Trichomoniasis Vaginal candidiasis BV
200–500 0.9 (0.7–1.2) 1.6 (1.2–2.1) 1.0 (0.8–1.2)
<200 0.7 (0.5–1.0) 1.6 (1.1–2.2) 1.3 (1.0–1.8)
AOR = adjusted odds ratio; CI = confidence interval; BV = bacterial vaginosis
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Table 6
Multivariate analyses of factors associated with gonorrhoea and Chlamydia in the
study population (n = 2292)
AOR (95% CI)
Associated factor Gonorrhoea Chlamydia
Sociodemographic
Mothers age at enrolment
Five year increase in age 0.9 (0.8–1.0) 1.0 (0.9–1.0)
Years of education
One year increase 1.0 (0.9–1.1) 1.0 (0.9–1.1)
Partner’s years of education
One year increase 1.0 (0.9–1.2) 1.0 (0.9–1.1)
Spouse’s occupation
Self–employed –
Formal employment – 0.9 (0.5–1.6
None – 1.1 (0.2–5.0)
Other – 0.5 (0.1–4.0)
Site
Lusaka 1.0 1.0
Blantyre 0.5 (0.1–4.2) 0.1 (0–5.0)
Lilongwe 7.5 (2.4–23.7) 0 (0–0.2)




2 1.2 (0.4–3.7) 0.8 (0.3–2.1)
3 2.8 (1.0–8.1) 1.2 (0.5–2.8)
4 1.9 (0.4–8.5) 1.3 (0.5–3.5)
5+ 2.6 (0.7–10.4) 0.4 (0.1–1.5)
Received treatment for genital ulcers during the past year
No 1.0 1.0
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AOR (95% CI)
Associated factor Gonorrhoea Chlamydia
>500 1.0 1.0
200–500 0.9 (0.4–2.1) 1.4 (0.6–2.9)
<200 0.7 (0.2–2.3) 1.3 (0.5–3.5)
AOR = adjusted odds ratio; CI = confidence interval; BV = bacterial vaginosis
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